Experimental drug combo targets tough bone cancer
NCT ID NCT04833582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug called azenosertib (ZN-c3) combined with the chemotherapy gemcitabine in 31 people aged 12 and older with osteosarcoma that had relapsed or stopped responding to treatment. The goal was to see if the combination is safe and whether it can slow or stop tumor growth. The study is now complete, and results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azenosertib (ZN-c3) combined with gemcitabine
What this could lead to
If it works, this could offer a new treatment option for people with osteosarcoma that has come back or not responded to standard therapy.
What could go wrong
This is an early phase 1/2 trial with only 31 participants, so results are preliminary. The combination may cause significant side effects and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 0103
Houston, Texas, 77030, United States
-
Site 0105
New York, New York, 10065, United States
-
Site 0106
Los Angeles, California, 90095, United States
-
Site 0107
Cincinnati, Ohio, 45229, United States
-
Site 0122
Seattle, Washington, 98195, United States
-
Site 0123
Portland, Oregon, 97239, United States
-
Site 0124
Oakland, California, 94609, United States
-
Site 0188
Richmond, Virginia, 23298, United States
-
Site 0193
Memphis, Tennessee, 38105, United States
-
Site 0195
Santa Monica, California, 90403, United States
-
Site 0197
Nashville, Tennessee, 37332, United States
-
Site 3601
Lyon, 69008, France
-
Site 3602
Marseille, 13385, France
-
Site 3604
Bordeaux, 33000, France
-
Site 3605
Toulouse, 31100, France
-
Site 3606
Paris, 75248, France
-
University of Florida College of Medicine
Gainesville, Florida, 32610, United States